Allergy and Airway |

The Effect of Omalizumab in Treatment of Inadequate Controlled Severe Persistent Asthma Patient FREE TO VIEW

Mohamed Zakaria, MD; Sandy Abu-Hussein, MD; Abdallah Abu-Hussein, MD; Mahmoud Ahmed, BA
Author and Funding Information

Cairo University, Cairo, Egypt

Chest. 2013;144(4_MeetingAbstracts):76A. doi:10.1378/chest.1703582
Text Size: A A A
Published online


SESSION TITLE: Asthma Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: We determined the effect of omalizumab on clinically significant asthma exacerbations (requiring systemic corticosteroids).

METHODS: Following a run-in phase, patients (12-75 years) inadequately controlled with high-dose inhaled corticosteroids (ICS) and long-acting beta(2)-agonists (LABA) with reduced lung function and a recent history of clinically significant exacerbations were randomized to receive omalizumab or placebo for 24 weeks in a double-blind, parallel-group study.

RESULTS: A total of 51 patients were included in the efficacy analyses. (30 treated with omalizumab), 95% of whom had severe persistent asthma according to the Global Initiative for Asthma (GINA) 2011 update. Omalizumab significantly reduced the rate of asthma exacerbations by 40% (P < 0.0001 vs control) and the rate of total emergency visits by 44% (P < 0.0001 vs control). Omalizumab significantly improved asthma-related quality of life, morning peak expiratory flow and asthma symptom scores.

CONCLUSIONS: In patients with inadequately controlled severe persistent asthma, despite high-dose ICS and LABA therapy, omalizumab significantly reduced the rate of clinically significant asthma exacerbations, severe exacerbations and emergency visits.


DISCLOSURE: The following authors have nothing to disclose: Mohamed Zakaria, Sandy Abu-Hussein, Abdallah Abu-Hussein, Mahmoud Ahmed

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543